Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag CancerVax Inc. expands research to target rare liver cancers with a new immune-boosting platform.

flag CancerVax Inc. is expanding its preclinical program to include rare forms of liver cancers, HCC, and ICC, using its innovative platform that targets cancer cells without harming healthy ones. flag The company's lipid nanoparticles detect cancer cells and mark them for the immune system to destroy. flag This expansion adds to their existing work on pancreatic cancer, aiming to address significant unmet needs with a universal treatment approach that could provide off-the-shelf cancer therapies.

4 Articles